Noubar Afeyan: New drug research challenges views on scientific progress and federal funding

Noubar Afeyan: New drug research challenges views on scientific progress and federal funding
Afeyan: Drug research challenges old views

Innovative pharmaceuticals are challenging long-held assumptions about the nature of scientific advancement.

Noubar Afeyan drew attention to a recent report from the New York Times, which examines how a newly developed drug is altering conventional wisdom in the field. Afeyan underscored the idea that substantial scientific breakthroughs are frequently rooted in notions that were initially dismissed as unattainable. He also pointed to the importance of federally funded basic research in powering discoveries. The developments described further raise questions about the dynamics and value of public investment in driving innovation.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.